Posts

Tagrisso approved in Japan for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

  AstraZeneca’s  Tagrisso  (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery. This approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the global ADAURA Phase III trial. While up to 30% of all patients with NSCLC may be diagnosed early enough to have surgery with curative intent, recurrence is still common in early-stage disease. 1,2  Historically, over half of patients diagnosed in Stage II, and approximately three quarters of patients diagnosed in Stage III, have experienced recurrence within five years of resection. 3,4  In Japan, lung cancer is the leading cause of cancer death and among patients with NSCLC, more than 35% have tumours with an EGFR mutation. 5,6 Masahiro Tsuboi, MD, PhD, Chief and Director, Department of Thoracic Surgery & Oncology, National Cancer Center Hospit...
Post a Comment
Read more

Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

  Sorrento Therapeutics  SRNE moved up 6.21% in August, during market hours, after the drugmaker announced positive results from its drug candidate, Abivertinib. The drug is being evaluated for treating advanced non-small cell lung cancer (NSCLC) patients resistant to first-line EGFR kinase inhibitor therapies. Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor being evaluated by Sorrento in a pivotal late-stage study in China. The company reported an overall response rate (ORR) of 56.5% (118/209) in 209 evaluable NSCLC patients being treated with abivertinib. The candidate also exhibited a complete response rate (CRR) of 5.3% (11/209) and median overall survival (OS) of 28.2 months in the aforementioned patient population. Sorrento is ending the study of abivertinib, and based on this data, it will be preparing to apply for a pre-new drug application (NDA) meeting with the FDA. The company also intends to submit documentation for th...
Post a Comment
Read more

What’s New in Equine Orthobiologics?

  Understanding this exciting yet complex field of regenerative medicine The idea, of course, is brilliant: Collect, enhance, and reintroduce horses’ own natural healing powers, so they can heal better. Such is the concept behind orthobiologics—the use of biological products such as stem cells and blood components to treat damaged musculoskeletal systems. It merges orthopedics—the branch of medicine concerned with the skeleton and associated structures, such as tendons and ligaments—and biologics, which in this context are naturally derived substances with healing properties. Despite its growing popularity, the field of orthobiologics remains fraught with confusion, contradiction, and questions. Fortunately, researchers are addressing those issues relentlessly, having published nearly 100 studies and reviews in the past year. Our sources share updates from the equine world to help you understand these therapies. Mother Nature’s Sustainable Regenerators Musculoskeletal injuries heal...
Post a Comment
Read more

HBOT-India launches medical grade Hyperbaric Oxygen therapy in Gurgaon

  The first 3 ATA Medical Grade Hyperbaric Oxygen Machine has been installed in Gurgaon, India. Adding Hyperbaric Oxygen Therapy (HBOT) reduces the risk of major amputation by around 20-30% and increases wound healing rate of around 10 times.  HBOT services are in high demand in South Asia. Of the 88mn infected with diabetes, 77mn live in India. Approximately 25% develop Diabetic Foot Ulcers (DFU), of which 50% become infected, requiring hospitalisation, while 20% need amputation. Further benefits of Hyperbaric Oxygen are not just limited to Diabetic Foot Ulcer treatment but stretch wider into many diseases and conditions including strokes and brain-related disorders. The HBOT machine has been installed in collaboration with Health Care at home, Guru Harikrishn Foundation and Art of Health Cancer. Manjit Singh, Founding Director at Guru Harikrishn Foundation, said, “As Hyperbaric oxygen therapy is supportive in various medical conditions and is the first of...
Post a Comment
Read more

From the robo-surgeon that killed its patient to the driverless car that ran over a pedestrian: Worst robotic accidents in history - after chess robot breaks seven-year-old boy's finger in Russia

  The robot grabbed the seven-year-old boy's finger at the Moscow Open last week because it was confused by his overly-quick movements, Russian media outlets reported.  Sergey Lazarev, vice-president of the Russian Chess Federation, said the child had violated 'certain safety rules' by making a move too soon.  Lazarev said that the machine had been hired for many previous events without any problems, and that the incident was an 'extremely rare case'.  Christopher Atkeson, a robotics expert at Carnegie Mellon University, told MailOnline: 'Robots have limited sensing and thus limited awareness of what is going on around them. 'I suspect the chess robot did not have ears, and that its vision system was blind to anything other than chess boards and pieces.'  Although the young chess player only suffered a broken finger, in other accidents involving robots the injured party has not always been as lucky.  MailOnline has taken a look at some of the disa...
Post a Comment
Read more